The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma.
Michael Platten
No relevant relationships to disclose
Harald Fricke
Employment or Leadership Position - Apogenix
Klaus Junge
No relevant relationships to disclose
Grigory Kobyakov
No relevant relationships to disclose
Tobias Martens
No relevant relationships to disclose
Oliver Heese
No relevant relationships to disclose
Benedikt Wiestler
No relevant relationships to disclose
Maximilian G Schliesser
No relevant relationships to disclose
Andreas von Deimling
No relevant relationships to disclose
Josef Pichler
No relevant relationships to disclose
Elena Vetlova
No relevant relationships to disclose
Inga Harting
No relevant relationships to disclose
Juergen Debus
No relevant relationships to disclose
Christian Hartmann
No relevant relationships to disclose
Claudia Kunz
Employment or Leadership Position - Apogenix
Martin Bendszus
Consultant or Advisory Role - Roche
Stephanie E. Combs
No relevant relationships to disclose
Wolfgang Wick
Consultant or Advisory Role - Apogenix (U); MSD; Roche
Honoraria - Roche
Research Funding - Apogenix; Boehringer Ingelheim; Roche